Status:
TERMINATED
Long-Term Safety of Pharmaceutical Grade Synthetic Cannabidiol Oral Solution in Pediatric Participants With Treatment-Resistant Childhood Absence Seizures
Lead Sponsor:
Radius Pharmaceuticals, Inc.
Collaborating Sponsors:
Benuvia Therapeutics Inc.
Conditions:
Childhood Absence Epilepsy
Eligibility:
All Genders
3-17 years
Phase:
PHASE2
Brief Summary
The primary purpose of this study is to assess the long-term safety and tolerability of Cannabidiol Oral Solution (CBD) in pediatric participants with treatment-resistant childhood absence seizures.
Eligibility Criteria
Inclusion
- Completed all activities through Visit 6 (End of Study) of INS011-17-103.
- Participant and/or parent(s)/caregiver(s) fully comprehend the informed consent form (ICF) and assent form, understand all study procedures, and can communicate satisfactorily with the investigator and study coordinator, in accordance with applicable laws, regulations, and local requirements.
- A female participant is eligible to participate in the study if she is premenarchal, or of childbearing potential with a negative urine pregnancy test at the Screening Visit. If sexually active, she must agree to either complete abstinence from intercourse or use acceptable methods of contraception throughout the study and for 4 weeks after completion of study participation or discontinuation from investigational product.
- A sexually active male participant or partner of enrolled participant must be willing to use acceptable methods of contraception throughout the study and for 4 weeks after completion of study participation or discontinuation from investigational product.
- In the opinion of the investigator, the parent(s)/caregiver(s) is (are) willing and able to comply with the study procedures and visit schedules, including venipuncture, and the visit schedules.
Exclusion
- Participant or parent(s)/caregiver(s) have daily commitments during the study duration that would interfere with attending all study visits.
- Experienced an anoxic episode related to study drug requiring resuscitation during their previous study.
- Developed an adverse event thought to be related to CBD in the previous study and for whom the Investigator determines that continuing treatment with CBD would not be in the best interest of the participant.
- Evidence of other clinically significant disease such as unstable hepatic, hematological, renal, cardiovascular, gastrointestinal, immunological, or pulmonary diseases or ongoing malignancies.
- Compromised respiratory function or severe respiratory insufficiency.
- Clinically significant abnormal laboratory values within the past 14 days.
- In the opinion of the investigator, the participant is unsuitable in any other way to participate in this study.
Key Trial Info
Start Date :
February 20 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 28 2019
Estimated Enrollment :
11 Patients enrolled
Trial Details
Trial ID
NCT03355300
Start Date
February 20 2018
End Date
June 28 2019
Last Update
June 18 2023
Active Locations (9)
Enter a location and click search to find clinical trials sorted by distance.
1
Nicklaus Children's Hospital
Miami, Florida, United States, 33155
2
Pediatric Epilepsy and Neurology Specialists
Tampa, Florida, United States, 33609
3
Clinical Integrative Research Center of Atlanta
Atlanta, Georgia, United States, 30328
4
Akron Children's Hospital
Akron, Ohio, United States, 44308